Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12071889 | 1.00 | ULK1 (0.47) | ULK1MEN1KMT2ASMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL1695681 | 0.98 | ULK1 (0.46) | ULK1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL7582068 | 0.88 | ULK1 (0.54) | ULK1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL16664407 | 0.83 | GAA (0.50) | MEN1KMT2ASMN1; SMN2HTTNPC1 | |
| SCHEMBL2484664 | 0.83 | GAA (0.50) | MEN1KMT2ASMN1; SMN2HTTNPC1 | |
| SCHEMBL13241014 | 0.83 | GAA (0.50) | MEN1KMT2ASMN1; SMN2HTTNPC1 | |
| SCHEMBL2488739 | 0.83 | SMN1; SMN2 (0.47) | ULK1MEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL1696009 | 0.82 | SMN1; SMN2 (0.51) | ULK1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL13240819 | 0.82 | SMN1; SMN2 (0.51) | ULK1MEN1KMT2ASMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL2486567 | 0.82 | GAA (0.49) | MEN1KMT2ASMN1; SMN2HTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376489-B1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMA SPA (IT) | 2015-04-22 | — | — | EP | claimed |
| US-8455646-B2 | Alkaloid aminoester derivatives and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-04 | — | — | US | claimed |
| EP-2376489-A1 | Alkaloid aminoester derivatives and medicinal composition thereof | Chiesi Farmaceutici S.p.A. (IT) | 2011-10-19 | — | — | EP | claimed |
| US-20100173880-A1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-07-08 | — | — | US | claimed |
| WO-2010072338-A1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-07-01 | — | — | WO | claimed |
| EP-2376489-B1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMA SPA (IT) | 2015-04-22 | — | — | EP | disclosed |
| US-8835682-B2 | Alkaloid aminoester derivatives and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-20130196978-A1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-08-01 | — | — | US | disclosed |
| US-8455646-B2 | Alkaloid aminoester derivatives and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-04 | — | — | US | disclosed |
| US-20100173880-A1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-07-08 | — | — | US | disclosed |
| WO-2010072338-A1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-07-01 | — | — | WO | disclosed |
| EP-1242069-A2 | ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES | EXOCELL, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001003684-A2 | ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES | EXOCELL, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196978-A1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHRM3, CHRM1, CHRNG | ULK1 2434/4885MEN1 4121/4885KMT2A 1874/4885 |
| US-20100173880-A1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHRM3, CHRM1, CHRNG | ULK1 2434/4885MEN1 4121/4885KMT2A 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.